Industry
Biotechnology
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
7.15
Mkt cap
183M
Volume
111K
High
7.15
P/E Ratio
-1.70
52-wk high
19.30
Low
5.52
Div yield
N/A
52-wk low
3.72
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 1:45 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 8:36 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 8:33 pm
Portfolio Pulse from Benzinga Insights
April 12, 2024 | 12:09 pm
Portfolio Pulse from Avi Kapoor
April 10, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
March 13, 2024 | 11:01 am
Portfolio Pulse from Benzinga Insights
March 07, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
March 07, 2024 | 3:59 pm
Portfolio Pulse from Benzinga Newsdesk
March 07, 2024 | 3:55 pm
Portfolio Pulse from Benzinga Newsdesk
March 07, 2024 | 1:14 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.